| Name | Title | Contact Details |
|---|---|---|
Scott Rossi |
Head of Cybersecurity | Profile |
Nightstar is a private biopharmaceutical company focused on the development of therapies for retinal dystrophies. The Company’s lead programme is a retinal gene therapy for choroideremia, a rare inherited cause of blindness that affects around 1 in 50,000 people. Gene therapy has the potential to be an effective treatment for choroideremia and a range of other retinal dystrophies. The Company’s lead investors are Syncona LLP and NEA Inc. Syncona is an evergreen investment company, taking an active role in identifying, supporting and developing technologies with the potential to impact significantly the healthcare market of the future. NEA is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies.
Manhattan Research is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
RESULTS ARE IN OUR DNA Fostering partnerships within the Life Science industry to enable innovation and positive outcomes. CLIENTS JOB SEEKERS Company We Are Precision Life Sciences Precision Life Sciences, a WBE (Woman-Owned Business Enterprise), was ...
NS Pharma is a biopharmaceutical company focused on researching and developing treatments for rare diseases, with a current focus on optimizing exon skipping therapy for Duchenne muscular dystrophy.